← Back to Search

Herbal Supplement

Synbiotic for Human Microbiome (TRIPH2017 Trial)

N/A
Waitlist Available
Led By Christine T Peterson, PhD
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights

TRIPH2017 Trial Summary

This trial looks at the potential benefits of taking a combination of probiotics and herbal supplements to improve gut health and reduce inflammation.

Eligible Conditions
  • Human Microbiome

TRIPH2017 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective Measures of Gut Microbiome Health
Secondary outcome measures
Inflammatory Biomarkers

Side effects data

From 2020 Phase 2 trial • 20 Patients • NCT02124759
14%
Vasovagal Syncope
14%
Nausea
14%
Abdominal Bloating/Flatulence
14%
Mouth Ulcers
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Sevelamer
Synbiotic

TRIPH2017 Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: SynbioticExperimental Treatment1 Intervention
Two grams of organic Triphala powder (Banyan Botanicals, Inc.) with 1 capsule VSL#3® (VSL Pharmaceuticals, Inc.) probiotic taken with a few ounces of room temperature water in the morning and at bedtime for 8 weeks. Subjects will be provided both written and verbal instructions and given a kit containing encapsulated Organic Triphala powder (Banyan Botanicals, Inc.) and VSL#3® (VSL Pharmaceuticals, Inc.) capsules.
Group II: ProbioticActive Control1 Intervention
Subjects will be provided both written and verbal instructions and given a kit containing encapsulated Organic Triphala powder (Banyan Botanicals, Inc.). Subjects will take 2 grams of organic Triphala powder with a few ounces of room temperature water in the morning and at bedtime.
Group III: PlaceboPlacebo Group1 Intervention
Subjects will be provided both written and verbal instructions and given a kit containing placebo capsules. Subjects will be instructed to take 2 (inert) capsules with room temperature water in the morning and at bedtime.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Synbiotic
2016
Completed Phase 3
~1290

Find a Location

Who is running the clinical trial?

University of California, San DiegoLead Sponsor
1,121 Previous Clinical Trials
1,521,350 Total Patients Enrolled
Christine T Peterson, PhDPrincipal InvestigatorUniversity of California, San Diego

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there opportunities for enrollment in this clinical trial presently?

"The clinicaltrial.gov database suggests that currently this trial isn't recruiting patients, as its last update was on January 18th 2021. However, 356 other studies are open for inclusion at the moment."

Answered by AI

Who else is applying?

What state do they live in?
Texas
California
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Effects of Triphala and VSL#3 Probiotic Supplementation on Stool Microbiome Profiles and Inflammation
Christine T. Peterson 2019. "Effects of Triphala and VSL#3 Probiotic Supplementation on Stool Microbiome Profiles and Inflammation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03907501.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top